Bristol-Myers Squibb Co.

NYSE:BMY   3:59:59 PM EDT
60.76
+0.73 (+1.22%)
Other Pre-Announcement, Mergers / Acquisitions

Bristol Myers Squibb To Acquire Myokardia For $13.1 Bln In Cash

Published: 10/05/2020 10:38 GMT
Bristol-Myers Squibb Co (BMY) - Bristol Myers Squibb to Acquire Myokardia for $13.1 Billion in Cash.
Bristol Myers Squibb to Acquire Myokardia for $13.1 Billion in Cash.
Bristol-myers Squibb Co - Deal Expected to Be Accretive to Non-GAAP Earnings Starting in 2023.
Bristol-myers Squibb Co - Bristol Myers Squibb Will Acquire Myokardia for $13.1 Billion, Or $225.00 per Share in Cash.
Bristol-myers Squibb Co - Expected to Be Accretive to Non-GAAP Earnings Starting in 2023.
Bristol-myers Squibb Co - Transaction Was Unanimously Approved by Both Bristol Myers Squibb and Myokardia Boards.
Bristol-myers Squibb Co - Reaffirms Its Existing 2021 Non-GAAP EPS Guidance Range.
Bristol-myers - Deal Expected to Be Minimally Dilutive to Bristol's Non-GAAP EPS in 2021 and 2022 and Accretive Beginning in 2023.
Bristol-myers Squibb Co - Expects to Finance Acquisition With a Combination of Cash and Debt.
Bristol-myers Squib - Expects to Explore Full Potential of Mavacamten in Additional Indications, Including Non-obstructive Hcm.